In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 19, No. 23 ( 2001-12-01), p. 4298-4304
Abstract:
PURPOSE: To test the hypotheses of whether the relative mRNA expression of the thymidylate synthase (TS) gene and the excision cross-complementing (ERCC1) gene are associated with response to and survival of fluorouracil (5-FU)/oxaliplatin chemotherapy in metastatic colorectal cancer. PATIENTS AND METHODS: Patients had progressive stage IV disease after unsuccessful 5-FU and irinotecan chemotherapy. All patients were evaluated for eligibility for a compassionate 5-FU/oxaliplatin protocol. cDNA was derived from paraffin-embedded tumor specimens to determine TS and ERCC1 mRNA expression relative to the internal reference gene beta-actin using fluorescence-based, real-time reverse transcriptase polymerase chain reaction. RESULTS: The median TS gene expression level from 50 metastasized tumors was 3.4 × 10 −3 (minimum expression, 0.18 × 10 −3 ;maximum expression, 11.5 × 10 −3 ), and the median ERCC1 gene expression level was 2.53 × 10 −3 (minimum, 0.0; maximum, 14.61 × 10 −3 ). The gene expression cutoff values for chemotherapy nonresponse were 7.5 × 10 −3 for TS and 4.9 × 10 −3 for ERCC1. The median survival time for patients with TS ≤ 7.5 × 10 −3 (43 of 50 patients) was 10.2 months, compared with 1.5 months for patients with TS greater than 7.5 × 10 −3 (P 〈 .001). Patients with ERCC1 expression ≤ 4.9 × 10 −3 (40 of 50 patients) had a median survival time of 10.2 months, compared with 1.9 months for patients with ERCC1 expression greater than 4.9 × 10 −3 (P 〈 .001). A TS of 7.5 × 10 −3 segregated significantly into response, stable disease, and progression (P = .02), whereas the association between ERCC1 and response did not reach statistical significance (P = .29). CONCLUSION: These data suggest that intratumoral ERCC1 mRNA and TS mRNA expression levels are independent predictive markers of survival for 5-FU and oxaliplatin combination chemotherapy in 5-FU–resistant metastatic colorectal cancer. Precise definition of the best TS cut point will require further analysis in a large, prospective study.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.2001.19.23.4298
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2001
detail.hit.zdb_id:
2005181-5
detail.hit.zdb_id:
604914-X
Permalink